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Abstract
Aims One prevalent comorbidity of chronic heart failure (CHF) is chronic kidney disease(CKD). Hyperkalemia is associated
with both CHF and CKD, which often leads to withdrawal of heart failure medications in clinical praxis.
Methods and results A patient is presented who suffered from acute kidney injury with pre-existing CKD as heart failure
comorbidity and a history of hyperkalemia.
Conclusions This case shows that potassium levels remained stable in acute kidney injury under ongoing heart failure
medications, including an MRA, with the use of the potassium binder patiromer.
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Introduction
In chronic heart failure (CHF), chronic kidney disease (CKD) is
one of the most prevalent co-morbidities.1 Patients with CHF
and CKD show a worse prognosis than those without CKD.2
The close interaction of the heart and the kidney was de-
scribed by the term cardiorenal syndrome (CRS) depending
on intra-renal haemodynamics, trans-renal perfusion pres-
sures, and neurohormonal factors.3 Associated with CRS is
the problem of derailment of electrolytes especially a high in-
cidence of hyperkalaemia. The risk of hyperkalaemia in HF is
further increased by guideline-recommended drugs improv-
ing mortality and morbidity like mineralocorticoid antagonists
or renin–angiotensin system inhibitors (RASi).4 New potas-
sium binders, like patiromer5 or ZS9,6 have been shown to
be effective in the treatment of hyperkalaemia and will be
assessed in HF to enable adequately dosed mineralocorticoid
receptor antagonists (MRAs), RASi, and sacubitril/valsartan.7
Case report
A 69-year-old woman presented with shortness of breath,
dizziness, and vomiting in the emergency room. The patient
reported not to have drank and eaten for 48 h with limited
sleep with consecutive socio-psychological stress owing to
grief over the loss of a loved one. According her past med-
ical history, the patient has been suffering from CHF disease
due to ischaemic cardiomyopathy with a systolic ejection
fraction of 28% at the last visit in the HF clinic. Because of
a bradycardia–tachycardia syndrome in connection with
atrial fibrillation, a pacemaker was implanted. Because of
haemodynamically relevant ventricular tachycardia and re-
duced ejection fraction before, the pacemaker was
upgraded to an implanted cardioverter defibrillator. She
was recently discharged after an acute HF decompensation.
Before admission, there was an interrogation of implantable
cardioverter defibrillator. There was an atrial pacing of 76%
with less than 0.1% ventricular pacing with no episodes of
ventricular tachycardia or persisting atrial fibrillation de-
tected. The medical treatment at discharge consisted of
bisoprolol 5 mg/day, sacubitril/valsartan 24/26 mg,
spironolactone 25 mg/day, and 80 mg of torasemide. In ad-
dition, peripheral arterial occlusive disease, coronary artery
disease, and liver cirrhosis were other relevant co-
morbidities. The patient was suffering from CKD with day-
to-day variations of estimated glomerular filtration rates
(eGFRs8; Chronic Kidney Disease Epidemiology Collaboration
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equation) between 25 and 40 mL/min/1.73 m2. Also accord-
ing her past medical history, she has been hospitalized re-
currently owing to acute-on-chronic kidney failure with
consecutive hyperkalaemia. Because even small reductions
of renal function in this patient were accompanied by
hyperkalaemia episodes with serum potassium up to
6.2 mmol/L previously, therapy with patiromer 8.4 g/day
was established after discharge from the previous hospital
stay 6 months ago.
Physical examination on admission revealed dry mucosa
and standing skin folds. The patient presented with im-
paired orientation. At hospitalization (Day 1 in Figure 1A–
D), lab values showed high creatinine of 3.2 mg/dL, eGFR
of 14.1 mL/min/1.73 m2, and urea of 242 mg/dL but still
normal potassium of 4.0 mmol/L on patiromer. Creatinine
and urea concentrations were higher and eGFR significantly
lower than the average outpatient values after the previous
HF hospitalization, which were also accompanied by im-
paired renal function. Other electrolytes showed normal
values. Electrocardiogram showed sinus rhythm with atrial
pacing with intrinsic atrioventricular transition that
persisted throughout the hospitalization. The patient was
not suffering from palpitations at admission or during
hospitalization.
Therapy
Upon physical examination, elevated creatinine and urea led
to the diagnosis of acute kidney failure due to exsiccosis.
Physical examination and medical history were suggestive of
volume depletion, but interestingly, potassium concentra-
tions were in the normal range. Therefore, volume was
substituted with electrolyte solutions with 2 L in the first
24 h and another 3 L in the subsequent 2 days. Under fluid
therapy, creatinine value decreased to 3.0 mg/dL at Day 1
(Figure 1A). Continuing fluid therapy lowered creatinine
levels to 1.96 mg/dL corresponding to her former creatinine
levels. In parallel, urea levels decreased from 242 to
126 mg/dL (Figure 1C), and creatinine–eGFR levels increased
from 15.4 to 35.8mL/min/1.73 m2 (Figure 1B). Serum sodium
concentrations decreased from 147 to 136 mmol/L during
fluid therapy (Figure 1E). Initially, potassium was at
4.2 mmol/L at a patiromer dose of 8.4 mg twice a day. At
the following days, potassium level was kept stable between
3.7 and 4.0 mmol/L (Figure 1D). On Day 5, we were able to
up-titrate spironolactone to 50 mg/day (Figure 1D) to
intensify HF treatment without rise of potassium. Blood
pressure was kept stable between systolic 120 mmHg and
Figure 1 A 69-year old female patient presented with acute kidney failure with increased serum creatinine and serum urea and decreased serum cre-
atinine–eGFR. Under ongoing heart failure medication and patiromer, serum potassium values could be kept stable. At acute hospitalization, serum
creatinine (A) was at 3.2 mg/dL, serum creatinine–eGFR (B) at 14 mL/min/1.73 m2, elevated serum urea (C) at 237 mg/dL, and serum sodium at
146 mmol/L (E). Under fluid therapy in the next 3 days, these values improved and reached output value. Potassium value (D) could be kept stable
at output value throughout the acute kidney failure accompanied with stable blood pressure values during acute hospitalization (F). At Day 5, even
up-titration of spironolactone was possible. Big blue circles indicate value at index event when patiromer was started; small blue circles, average value
under patiromer before acute hospitalization; green circles, values before taking of patiromer; yellow circles, value after 3 months’ control. DBP, dia-
stolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.
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diastolic 60 mmHg (Figure 1F). All parameters were stable in
3 months’ control under ongoing HF and patiromer therapy
(Figure 1A–E).
Hyperkalaemia represents an important clinical problem,
because the frequent CRS is associated with impaired
potassium excretion9 and with high mortalitiy.10 Mortality
and morbidity are reduced by guideline-directed MRAs and
RASi, although these drugs can lead to or augment
life-threatening hyperkalaemias.11 In clinical praxis, physicians
often continuously stop or do not up-titrate potassium-
retaining drugs like spironolactone despite their benefits on
outcomes.12 A recent study showed that only 54% of
hyperkalaemia episodes were directly associated with MRA
therapy, while on placebo, hyperkalaemia occurred also in
46%.13 In consequence, 46% were related to other reasons,13
but hyperkalaemia workup is often dismissed.14 The Guide-
lines of the European Society of Cardiology recommend not
only to continuously withdraw but also to intermittently
pause renin–angiotensin–aldosterone system (RAAS) inhibitor
therapy until the workup of hyperkalaemia is finished. Even
though RAAS blockers can frequently cause a decrease in
eGFR, the treatment benefit in these patients is maintained.15
Pathophysiology of hyperkalaemia involves either extracel-
lular potassium shifts or decreased renal excretion.15 Approx-
imately 73% of patients with advanced CKD and 40% of HF
patients may be at risk of elevating potassium levels.16 Equiv-
alent to reasons, treatment of hyperkalaemia consists either
of shifting potassium into cells via insulin/glucose, with
beta-agonists activating the Na+-KATPase or sodium bicar-
bonate. The other approach consists of elimination of potas-
sium from the body by diuretic therapy o haemodialysis.15 A
new approach for suppressing hyperkalaemia in CKD and HF
is the potassium binder patiromer.17–19 The active moiety of
patiromer is a non-absorbable oral K+-binding polymer that
primarily acts in the distal colon to increase faecal K+
excretion.20 In the OPAL-HK study, 2015 patients with CKD
on RAAS inhibitor medication were randomized to patiromer
or placebo. Patiromer lowered mean serum K+ compared
with placebo and also reduced the number of patients with
recurrent hyperkalaemia, allowing significantly more patients
to remain on RAAS inhibitor therapy.21 In the case presented
here, there was an impressive dissociation of creatinine and
urea concentrations and potassium levels on patiromer in
acute kidney injury, even though this patient had regular ep-
isodes of hyperkalaemia before as reason to treat her with
patiromer and include her in an observational patiromer
study (CONTINUE-HF NIS, DRKS-ID: DRKS00014825).
Effective treatment of arterial hypertension is essential to
prevent patients from developing CHF and CKD.22,23 Accord-
ing to European Society of Cardiology (ESC) Guidelines for
the treatment of hypertension, spironolactone is recom-
mended for patients with uncontrolled, resistant
hypertension.24 The AMBER trial evaluated whether the use
of patiromer allows persistent use of spironolactone in pa-
tients with CKD and resistant hypertension. More patients
(86% vs. 66%) on patiromer therapy were able to continue
treatment with spironolactone with less hyperkalaemia as
compared with those on placebo.25
One might ask why this patient suffered from acute kidney
injury. The patient was discharged after an acute decompen-
sation from the hospital. On admission, the patient presented
with generalized oedema and was recompensated with di-
uretics, and sacubitril/valsartan was added to the discharge
medication together with diuretics. Sacubitril/valsartan re-
duces diuretic demand in the PARADIGM trial26 and in
real-life conditions, when patients are being treated by their
family physicians27 owing to haemodynamic intrarenal and
natriuretic effects of the drug.28,29 Therefore, the reduced
fluid intake due to psychosocial stress as well the reduced di-
uretic demand under sacubitril/valsartan at high diuretic dis-
charge doses probably might have caused acute kidney injury
in this patient.
Taken together, this case study shows that potassium
levels can be kept stable even in acute kidney failure and on-
going HF medications and even in a patient with previous
hyperkalaemia with the use of potassium binder patiromer.
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